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Abstract
Background: Measurement of immune mediators and antimicrobial activity in female genital tract secretions may provide
biomarkers predictive of risk for HIV-1 acquisition and surrogate markers of microbicide safety. However, optimal methods
for sample collection do not exist. This study compared collection methods.
Methods: Secretions were collected from 48 women (24 with bacterial vaginosis [BV]) using vaginal and endocervical
Dacron and flocked swabs. Cervicovaginal lavage (CVL) was collected with 10 mL of Normosol-R (n = 20), saline (n = 14), or
water (n = 14). The concentration of gluconate in Normosol-R CVL was determined to estimate the dilution factor. Cytokine
and antimicrobial mediators were measured by Luminex or ELISA and corrected for protein content. Endogenous anti-HIV-1
and anti-E. coli activity were measured by TZM-bl assay or E. coli growth.
Results: Higher concentrations of protein were recovered by CVL, despite a 10-fold dilution of secretions, as compared to
swab eluents. After protein correction, endocervical swabs recovered the highest mediator levels regardless of BV status.
Endocervical and vaginal flocked swabs recovered significantly higher levels of anti-HIV-1 and anti-E. coli activity than
Dacron swabs (P,0.001). BV had a significant effect on CVL mediator recovery. Normosol-R tended to recover higher levels
of most mediators among women with BV, whereas saline or water tended to recover higher levels among women without
BV. Saline recovered the highest levels of anti-HIV-1 activity regardless of BV status.
Conclusions: Endocervical swabs and CVL collected with saline provide the best recovery of most mediators and would be
the optimal sampling method(s) for clinical trials.
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Introduction
Successful interventions to interrupt the HIV-1 epidemic,
particularly among women of reproductive age, are urgently
needed. While encouraging advances in the areas of both vaccines
and microbicides have recently been reported [1,2], attempts to
explain unsuccessful clinical trials [3,4,5,6,7] have prompted
efforts to better understand how HIV-1 is transmitted during
coitus [8] and to develop surrogate biomarkers of microbicide
safety [9]. In sub-Saharan Africa, heterosexual sex continues to
drive the epidemic, and women are disproportionately infected
[10]. The female genital tract (FGT) and in particular the mucosal
immune environment may influence HIV-1 acquisition and the
effectiveness of HIV-1 prevention modalities.
The FGT is an active immunological site that responds to
pathogens (e.g. HIV-1 or other sexually transmitted infections
[STIs]) yet accommodates a developing fetus. Sex hormones
produce cyclic changes in the FGT that regulate the cellular and
innate immune responses [11]. Epithelial cells are sentinel cells
and produce a number of soluble mediators that influence immune
cell migration and defense against local pathogens including HIV-
1 [12]. These mediators are released in response to concurrent/
recent STIs and may contribute to the biological and epidemio-
logical synergy between HIV-1 and STIs. The inflammatory
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response to STIs likely disrupts the protective epithelial barrier
and recruits and activates HIV-1 target cells that increase the risk
for HIV-1 acquisition [13,14,15]. Recruitment of activated target
cells plays a role in amplifying the initial HIV-1 transmitted
founder virus(es) [16] to a more diverse population fostering local
and systemic spread of infection [17]. Endogenous antimicrobial
activity, which presumably reflects the collective activity of
antimicrobial proteins, cytokines, chemokines, and vaginal micro-
flora, could affect HIV-1 susceptibility [18,19,20,21]. Thus,
measurement of individual mediators or functional activity may
provide biomarker(s) of risk for HIV-1 acquisition or disease
progression as well as serving as surrogate markers of microbicide
or mucosal vaccine safety. Most studies have focused on
quantifying cytokines, chemokines, and secretory leukocyte
protease inhibitor (SLPI) because of the central role of inflamma-
tion in promoting HIV-1 shedding [22,23]. Others have begun to
measure endogenous antimicrobial activity and/or concentrations
of antimicrobial peptides such as defensins [18,19]. However,
before biomarkers can be identified, tested, and validated, optimal
collection method(s) for measuring candidate biomarkers need to
be determined [19,24].
To address this gap, the concentrations of immune mediators
(cytokines, chemokines, defensins, SLPI, and lactoferrin [Lf]) and
antimicrobial activity (inhibition of E. coli and HIV-1) were
measured to evaluate whether the site of collection (direct swab of
vaginal or endocervical epithelium or cervicovaginal lavage
[CVL]), the collection method (Dacron swab, flocked swab or
CVL), or diluent of the CVL (saline, Normosol-R, or water)
effected recovery of biomarkers of soluble mucosal immunity. Sites
and collection methods were chosen based on sampling techniques
currently performed in clinical trials. The diluents for the CVL
were compared because of specific advantages each may have.
Saline is a physiologic solution and commonly obtained in clinics,
but the salts may inactivate defensins and interfere with the
assessment of the antimicrobial activity [25]. Normosol-R contains
gluconate, not present in genital secretions, which may provide a
quantitative correction for the dilution of recovered secretions
similar to LiCl [26]. Water is widely available, but because it is
hypotonic, its use is limited; water can lyse the cells and virus that
are targets for testing biological activity. Women with asymptom-
atic bacterial vaginosis (BV) were included because BV is a
common condition associated with an increased risk of HIV-1
acquisition and prevalent among women in sub-Saharan Africa
and may impact collection methods [27]. Our interest was to
determine the optimal sample collection method(s) for the
identification of relevant biomarker(s).
Methods
Study population and sample collection
Johns Hopkins University Institutional Review Board approved
the study (NA_00036496). Non-pregnant adult women aged 18–
45 and without genitourinary symptoms were recruited from the
Baltimore, MD metropolitan area. After providing written
informed consent, medical history was obtained to exclude women
with active menstruation, genitourinary symptoms, or clinically
apparent vaginal infections. Previous studies have shown mediator
recovery was not affected by the sequence of FGT sample
collection [28,29]. Therefore, among enrolled women, the
following were collected in sequence: cervical swab for AP-
TIMA2-Combo assay (GenProbe, San Diego, CA) for Chlamydia
trachomatis and Neisseria gonorrhoeae, Dacron swab (Cardinal Health,
McGraw Park, IL) of secretions from lateral vaginal wall for
preparation of saline microscopy to evaluate for trichomoniasis
and of Gram stain for assessment of Nugent criteria [30]; and for
the biomarker analyses, Dacron swab of secretions from lateral
vaginal wall, flocked swab (Seacliff Packaging, Inc., Newport
Beach, CA) of secretions from lateral vaginal wall, Dacron swab of
endocervical secretions, flocked swab of endocervical secretions,
and finally CVL with one of three diluents. Women were
randomly assigned to receive a 10 ml CVL of saline, tap water,
or Normosol-R pH 7.4 (Hospira, Inc., Lake Forest, IL). Normosol-
R is a sterile, isotonic balanced salt solution and contains 50.2 mg
sodium gluconate per 10 ml. All women with symptomatic BV
and STIs detected at screening were excluded and referred for
appropriate management. We selected these exclusion criteria
because they are typically employed in clinical trials studying
prevention of HIV.
Sample processing
CVL were clarified by centrifugation and supernatants divided
into 1 ml aliquots and stored at 280uC. Swabs were placed in
1 ml phosphate-buffered saline (pH 7) and stored at 280uC until
processed. Swabs were thawed on wet ice, vortexed for
approximately 10 seconds, and compressed against the side of
the tube to maximize elution of genital tract secretions. The swab
was transferred to a new, sterile 1.8 mL microfuge tube and stored
at 280uC. The original tube with the eluent was placed in a
refrigerated microfuge centrifuge and clarified at 7006g for
10 minutes. The eluent was divided into 100 ml aliquots and
stored at 280uC. Protein concentrations of CVL and swab eluents
were determined using the Bradford assay (Sigma-Aldrich, St.
Louis, MO).
Soluble immune mediators
Cytokines (GM-CSF, IL-1b, IL-6, and IL-12p40) and the
chemokine IL-8 were quantified in the CVL and swab eluents
using Luminex technology (25 ml of sample) (Millipore, Billerica,
MA). The sensitivities for these mediators were 9.5 pg/ml, 0.4 pg/
ml, 0.3 pg/ml, 0.2 pg/ml, and 10.5 pg/ml, respectively. The
mucosal innate immune mediators, Lf (EMD Chemicals, Gibbs-
town, NJ), SLPI (R&D Systems, Inc., Minneapolis, MN), human b
defensins (HbD) 1, 2, and 3 (Alpha Diagnostics, San Antonio, TX),
and defensin human neutrophil peptides 1–3 (HNP1–3; HyCult
Biotechnology, Uden, The Netherlands) were quantified by
ELISA. The limit of detection (LOD) for these commercial assays
were .1 ng/ml, ,25 pg/ml, 25 pg/ml, 5 pg/ml, 20 pg/ml, and
156 pg/ml, respectively. All ELISAs required 100 ml of sample to
perform the assay. Samples often needed to be diluted to be in the
linear range of the standard curve. When diluted, reagent diluent
for the specific ELISA was used. To standardize levels of the
mediators tested, concentrations were corrected by their respective
protein concentrations.
Antimicrobial activity
Antimicrobial activity against E. coli or HIV-1 was measured
in CVL and swab eluents. For anti-E. coli activity, CVL, swab
eluent, or control genital tract buffer (GTB; 20 mmol/l
potassium phosphate monobasic, 60 mmol/l sodium chloride,
0.2 mg/ml albumin, pH 4.5) was mixed with approximately
66109 colony-forming units (CFU)/ml of E. coli and incubated
at 37uC for two hours. The mixtures were then diluted 1000-
fold in GTB, mixed with overlay media and plated on agar
enriched with trypticase soy broth. Colonies were counted using
ImageQuant TL v2005 after an overnight incubation at 37uC.
All samples were tested in duplicate and the percent inhibition
determined relative to the colonies formed on control plates
(800–1000 CFU). For anti-HIV-1 activity, TZM-bl cells were
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plated at 30,000 cells per well overnight. The cells were treated
with CVL, swab eluent, or control buffer and challenged with
HIV-1BaL diluted (1:5) in media. After 48-hour incubation at
37uC, the supernatant was removed, cells were lysed, and
luciferase activity was measured in relative light units (Lucifer-
ase assay; Promega, Corp., Madison, WI). Mock infected cells
served as a negative control. All samples were tested in triplicate
in at least two independent experiments.
Figure 1. Sample collection algorithm. Sample collection proceed-
ed from the introitus to the cervix. A Dacron swab was rolled 360u along
the vaginal lateral wall. A flocked swab was rolled 360u along the
opposite vaginal lateral wall. After vaginal swabs, endocervical swabs
were taken with first a Dacron swab and then a flocked swab inserted
into the cervical os and turned 360u. Finally, the women were
randomized to have a CVL collected with 10 ml of saline, Normosol-R,
or tap water. Samples were processed as described in the Methods
section.
doi:10.1371/journal.pone.0023136.g001
Figure 2. Protein levels in female genital tract secretions
collected by swabs and cervicovaginal lavages (CVL). Female
genital tract secretions were collected by Dacron swabs (DS) and
flocked swabs (FS) from the vagina and the endocervix (cervix) and by
CVL using Normosol-R, saline, or water. Protein levels were determined
using the Bradford assay. Data are presented as box and whisker plots
where the median is the horizontal line through the vertical box which
represents the 25–75th percentiles. Values within the 10–90th percen-
tiles are represented by the error bars. Outliers are shown by filled
circles. Data were log-transformed and significant changes were
determined using linear mixed model and discussed in the results
section.
doi:10.1371/journal.pone.0023136.g002
Table 1. Levels of immune mediators and endogenous antimicrobial activity in female genital tract samples by collection sites and
methods.
Collection methoda DS Vag FS Vag DS Cer FS Cer CVL p-valued
Protein (mg/ml) 89c (18–1652) 205 (0–836) 174 (20–4365) 349.5 (18–6804) 694 (664–836) ,0.001
GM-CSF (pg/ml) 1.5 (0.5–3.0) 1.6 (0.5–8.1) 1.6 (0.5–11.5) 1.6 (0.5–15.8) 1.6 (0.5–7.1) ,0.001
IL-1b (pg/ml) 1.6 (0.1–83.4) 5.1 (0.1–214) 6.1 (0.2–711) 16.1 (0–1140) 5.8 (0.1–482.9) ,0.001
IL-6 (pg/ml) 0.3 (0.1–24.0) 0.5 (0.3–140) 17.2 (0.03–564) 42.1 (0.1–578) 8.6 (0.1–92.9) ,0.001
IL-8 (pg/ml) 340.0 (11.2–3744) 342.6 (0.1–2883) 1104 (21.3–13557) 1687 (121–5455) 202.3 (2.7–3186.3) ,0.001
IL-12p40 (pg/ml) 1.6 (0.1–9.1) 1.6 (1.1–8.4) 2.0 (0.2–17.0) 2.9 (0.2–35.0) 2.8 (0.1–48.5) ,0.001
Lf (ng/ml) 254.2 (2.4–2657) 294.2 (6.0–6213) 868.0 (2.0–8472) 1092 (9.8–14467) 282.2 (8.0–4776.7) ,0.001
SLPI (ng/ml) 219.5 (3.1–1361) 261.8 (4.7–3304) 411.3 (31.0–3222) 787.1 (68.6–4454) 253.2 (2.8–3908) ,0.001
HNP1-3 (mg/ml) 16.2 (4.7–520.5) 16.6 (4.6–507.5) 56.5 (2.4–321.8) 82.8 (5.4–594.8) 48.0 (16.0–4307) 0.02
Anti-E. coli (% inh.)b 27.5 (222–79) 50.5 (4–99) 25 (211–93) 59.5 (20.1–100) 78 (20–100) ,0.001
Anti-HIV-1 (% inh.) 49 (2188–91) 59 (242–100) 26.5 (2112-100) 63 (226–117) 48.5 (27–99.5) ,0.001
aDS Vag, Dacron vaginal swab; FS Vag, flocked vaginal swab; DS Cer, Dacron endocervical swab; FS Cer, flocked endocervical swab; CVL, cervicovaginal lavage.
b% inhibition – negative values reflect increased growth of E. coli or enhancement of infection of HIV-1.
cmedian (range).
dp-value: Global p-value based on the comparison of protein-adjusted, log-transformed immune mediators and endogenous antimicrobial activities by collection sites
and methods.
doi:10.1371/journal.pone.0023136.t001
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Gluconate assay
Gluconate in CVL effluent was assayed using a biochemical
two-step enzymatic conversion from gluconate to NADPH with
colorimetric detection of product at 340 nm (MegaZyme,
Wicklow, Ireland). By comparing the concentration of gluconate
in the lavage fluid with the gluconate in the CVL effluent, the
dilution of the cervicovaginal fluid was determined.
Statistical analysis
Descriptive statistics such as median and range were reported
for immune mediators and antimicrobial activity. Analysis of
variance (ANOVA) was performed to compare concentrations of
immune mediators and antimicrobial activity between different
diluents of CVL. Linear mixed-effect models that take into
account the correlation among repeated measures were used to
compare differences in the concentrations recovered by different
collection site and method, adjusting for BV (Nugent score $7). In
this analysis, the three CVL solutions were considered as one type
of collection method. To reduce skewness in the distribution,
protein-corrected, log-transformed concentrations of all the
immune mediators were used in linear mixed model and ANOVA
analyses. Spearman rank-order correlation was calculated to assess
correlations between mediators. Statistical analyses were per-
formed using SAS 9.2 (SAS, Cary, NC). All statistical tests were
two-sided, and P#0.05 indicated statistical significance.
Results
Study subjects
Forty eight women were enrolled. Mean (SD) age was 30.8
(67.1) years and ranged from 20–45 years. Women indicated the
following race: African-American (46%), white (40%), Asian
(12%), other (2%). BV was diagnosed in 24/48 (50%) of the
women; 23/48 (48%) had no evidence of BV and one was
indeterminate based on slide quality. After collection of vaginal
and then endocervical swabs, women were assigned to CVL
collection with Normosol-R (42%), saline (29%) or tap water
(29%) (Figure 1). Overall, recovery of CVL was 8.961.8 ml
regardless of diluent used.
Effect of collection method on genital tract secretions
and recovery of protein
Advantages of CVL collection includes recovery of all material
present in the lower genital tract, recovery of a greater volume of
material, and overcoming the difficulty of eluting secretions from
swabs. Disadvantages include altered mediator concentration due
to an unknown dilution factor. To address the disadvantages, the
concentration of gluconate in CVL collected in Normosol-R was
determined in 20 participants. The recovered cervicovaginal fluid
was 235 ml (139.2–304.8 ml; median [range]), a 42-fold dilution of
genital tract secretions in a 10 ml CVL. Swabs were not collected
in Normosol-R; consequently, the dilution of secretions from a
1 ml swab eluent could not be determined. However, total protein
concentration in CVL and swabs was measured. CVL collected
significantly higher (P,0.001) levels of protein as compared to
swabs. The variation in protein content was markedly lower with
CVL as compared to swabs (Table 1, Figure 2). The absolute
concentrations of each mediator (Table 1 and 2) are presented to
provide data on the range of values recovered. To adjust for
dilutional variability, the concentration of the soluble mediators
was corrected by its protein concentration in the subsequent
analyses.
For the CVL collected in 20 women with Normosol-R, the
variation in the correction index (individual correction divided by
average correction) was smaller for protein (6% coefficient of
variation [CV]) when compared to gluconate (23% CV); there was
no correlation between protein and gluconate (r = 0.20).
Recovery of cytokines and the chemokine IL-8
Because the levels of GM-CSF and IL-12p40 for the majority of
samples were below the LOD regardless of sampling site or
Table 2. Levels of immune mediators and endogenous antimicrobial activity in female genital tract samples by CVL diluents.
Collection methoda CVL (Normosol) CVL (Saline) CVL (Water) p-valuee
Protein (mg/ml) 724.5c (671–836) 688 (668–777) 692 (664–799) 0.43
GM-CSF (pg/ml) 1.5 (0.8–2.4) 1.6 (1.2–7.1) 1.3 (0.5–2.4) 0.02
IL-1b (pg/ml) 5.8 (0.1–483) 8.9 (0.2–204) 3.7 (0.2–39.0) 0.82
IL-6 (pg/ml) 9.5 (0.3–92.9) 9.5 (0.06–33.2) 4.9 (0.3–92.3) 0.85
IL-8 (pg/ml) 223.5 (9.0–3186) 328.3 (30.7–1866) 155.0 (2.7–1470) 0.26
IL-12p40 (pg/ml) 2.8 (0.1–12.2) 2.0 (1.5–48.5) 4.3 (1.6–10.0) 0.70
Lf (ng/ml) 364 (12.4–4777) 309 (50.1–785) 184.2 (8.0–1354) 0.84
SLPI (ng/ml) 284.3 (7.9–2624) 504.9 (13.4–3908) 32.6 (2.8–2710) 0.02
HNP1-3 (mg/ml) 34.8 (18.3–2204) 108 (16.2–1181) 57.1 (16.0–4307) 0.58
HbD-1 (pg/ml) 7732 (1102–16209) 4228 (822–12994) 995 (150–8009) 0.03
HbD-2 (pg/ml) 485 (96–818) 500 (96–633) 161.5 (9.6–538) 0.004
HbD-3 (pg/ml) 710 (182–2962) 1376 (175–11944) 228.5 (121–1113) ,0.001
Anti-E. coli (% inh.)b 79.5 (20–100) 62 (47–100) ntd 0.52
Anti-HIV-1 (% inh.) 41.3 (27–63) 68.5 (12–99.5) nt 0.008
aCVL, cervicovaginal lavage.
b% inhibition – negative values reflect increased growth of E. coli or enhancement of infection of HIV-1.
cmedian (range).
dnt = not tested.
ep-value: Global p-value based on the comparison of protein-adjusted, log-transformed immune mediators and endogenous antimicrobial activity by CVL diluents.
doi:10.1371/journal.pone.0023136.t002
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specimen collection method, they were not included in the
analyses. The recovery of cytokines and IL-8 differed significantly
with sampling site and method (P,0.001) (Table 1, Figure 3A).
Endocervical flocked swabs recovered the highest levels IL-1b and
IL-6 and endocervical Dacron swabs recovered the highest level of
IL-8. The presence of BV did not affect cytokine or IL-8 recovery
from the swab eluents.
Women with BV tended to have better recovery of IL-8
(P=0.02), IL-1b (not significant) and IL-6 (not significant) in CVL
collected with Normosol-R as compared to saline and water
(Table 2, Figure 2). The diluent type did not significantly impact
recovery of mediators in women without BV.
Recovery of antimicrobial mediators
Antimicrobial mediator recovery was similar to cytokine and IL-
8 recovery. Endocervical swabs recovered the highest levels of Lf
(P,0.001), SLPI (P,0.001), and HNP1–3 (P=0.02) as compared
to vaginal swabs and CVL (Table 1, Figure 3B). The presence of
BV did not affect Lf or HNP1–3 recovery. However, SLPI levels
were significantly reduced in women with BV (P=0.004), but
endocervical swabs still recovered higher levels than the other
swabs (Figure 4). Due to limited quantities of swab eluents, the
levels of b-defensins were not quantified.
The CVL diluents were not significantly different for Lf
recovery (Table 2, Figure 2B). CVL collected in Normosol-R
and saline recovered significantly higher levels (P,0.05) of the
three b-defensins as compared to water. BV did not affect the
recovery of Lf or the three b-defensins. However, higher levels of
SLPI and HNP1–3 were recovered by saline and water,
respectively in women without BV, while Normosol-R recovered
higher levels of both mediators in women with BV (Figure 4).
Endogenous antimicrobial activity in FGT secretions
The biological activity of the secretions was determined by
evaluating the ability of samples to inhibit E. coli or HIV-1 in vitro.
Because the contributors to inhibition could include mucins and
other non-proteinaceous molecules, the anti-microbial activity was
not corrected for protein content. CVL sampling with Normosol-
R and saline (P,0.001) recovered the highest amount of anti-E.
coli activity compared to the swabs (Table 1 and 2, Figure 5).
Flocked swabs (endocervical and vaginal) and CVL collected in
saline recovered comparable levels of anti-HIV-1 activity and were
Figure 3. Levels of mediators in female genital tract secretions collected by swabs and cervicovaginal lavages (CVL). Female genital
tract secretions were collected by Dacron swabs (DS) and flocked swabs (FS) from the vagina and the endocervix (cervix) and by CVL using Normosol-
R, saline, or water. (A) Cytokine levels and IL-8 were measured by luminex technology. (B) Antimicrobial protein levels were measured by
commercially available ELISA. b-defensins were measured only in CVL due to limited sample volume from the swabs. Data are presented as box and
whisker plots where the median is the horizontal line through the vertical box which represents the 25–75th percentiles. Values within the 10–90th
percentiles are represented by the error bars. Outliers are shown by filled circles. Data were log-transformed and significant changes were determined
using linear mixed model and discussed in the results section.
doi:10.1371/journal.pone.0023136.g003
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higher than the other collection methods (Table 1 and 2, Figure 5).
The reasons for significantly higher (P=0.001) recovery of anti-
HIV-1 activity among women without BV when CVL was
collected in saline as compared to Normosol-R are not known. No
differences in HIV-1 infection rates were observed when virus was
mixed with Normosol-R or saline prior to infecting TZM-bl cells
(data not shown). Water was not tested for antimicrobial activity as
the hypotonicity of the sample would lyse the cells and inactivate
the virus.
Correlations between mediators
The antimicrobial activity likely reflects the soluble mediators
acting in combination with each other in the FGT, thus
correlations between mediators were assessed. IL-1b was modestly
correlated with Lf (0.52, P,0.0001; r, P-value) and HNP1–3 (0.51,
P,0.0001). IL-6 was modestly correlated with Lf (0.50, P,0.0001)
and HNP1–3 (0.66, P,0.0001). IL-8 was modestly correlated with
Lf (0.68, P,0.0001), and HNP1–3 (0.67, P,0.0001). The anti-E.
coli activity was weakly, inversely correlated with SLPI (20.25,
P,0.0003). None of the mediators correlated to the anti-HIV-1
activity.
Discussion
Collection of mucosal secretions is commonly performed to test
for surrogate markers of product safety and efficacy in studies
aimed at testing interventions—such as microbicides and vac-
cines—to prevent HIV-1. However, biomarkers for these end-
points have proven elusive. Advancement of candidate biomarkers
is hampered by the various approaches used to collect genital tract
secretions and a paucity of data regarding optimal collection
methods, especially about issues that might affect sample collection
methods. This study is the first to directly compare the recovery of
key candidate biomarkers using different collection methods.
Endocervical swabs recovered significantly higher levels of most
mediators as compared to vaginal swabs or CVL when controlling
for recovered protein.
The finding that higher concentrations of most mediators were
recovered from endocervical sampling is consistent with earlier
work demonstrating that endocervical cells express higher
constitutive levels of cytokines and chemokines compared to
vaginal or ectocervical cells [31,32], suggesting that epithelial cell
function may vary at different anatomical sites in the FGT. The
stratified squamous epithelium of the lower FGT, which provides a
physical barrier to HIV-1, harbors intraepithelial lymphocytes and
Langerhans cells. In contrast, the endocervix is lined with a single
layer of columnar epithelium covering a lamina propria that is
Figure 4. Levels of secretory leukocyte protease inhibitor
(SLPI) in female genital tract secretions collected by swabs and
cervicovaginal lavages (CVL) in women without or with
bacterial vaginosis (BV). Female genital tract secretions were
collected by Dacron swabs (DS) and flocked swabs (FS) from the
vagina and the endocervix (cervix) and by CVL using Normosol-R, saline,
or water. Women with BV (n = 24) had a Nugent score of $7. Data are
presented as box and whisker plots where the median is the horizontal
line through the vertical box which represents the 25–75th percentiles.
Values within the 10–90th percentiles are represented by the error bars.
Data were log-transformed and significant changes were determined
using linear mixed model and discussed in the results section.
doi:10.1371/journal.pone.0023136.g004
Figure 5. Levels of antimicrobial activity in female genital tract
secretions collected by cervicovaginal lavages (CVL) and
swabs. Female genital tract secretions were collected by Dacron swabs
(DS) and flocked swabs (FS) from the vagina and the endocervix (cervix) and
by CVL using Normosol-R, saline, or water. Anti-E. coli activity was calculated
as the % inhibition of bacterial growth compared to an untreated control.
Anti-HIV-1 activity was calculated as the % inhibition of infection as
compared to an untreated control. CVL/water was not tested (nt) because
water would lyse the pathogens or cells providing non-reportable results.
Negative values reflect increased E. coli growth or enhanced HIV-1 infection.
Data are presented as box and whisker plots where the median is the
horizontal line through the vertical box which represents the 25–75th
percentiles. Values within the 10–90th percentiles are represented by the
error bars. Outliers are shown by filled circles. Significant changes were
determined using linear mixed model and discussed in the results section.
doi:10.1371/journal.pone.0023136.g005
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more populated with immune cells than the vaginal lamina
propria. This further suggests that endocervical sampling would
recover greater amounts of immune mediators secreted by a larger
number of immune cells than vaginal sampling.
Interestingly, the swab type (Dacron versus flocked) did not
significantly influence recovery of the immune mediators after
correcting for protein content. This has important economic
implications as flocked swabs are considerably more expensive
than Dacron. More protein was recovered from flocked swabs as
compared to Dacron swabs, which is consistent with their
composition. The flocked swab is made of perpendicular nylon
fibers that resemble a soft brush, whereas the Dacron swab is
composed of a polyester tip. While the swabs were not weighed,
the open weave of the flocked swab likely collected more material.
This may explain why flocked swabs were superior to Dacron
swabs for detection of STIs [33,34].
An advantage of collecting mucosal secretions by a swab is the
recovery of sample with minimal dilution. However, this may be
offset by the difficulty of eluting secretions from the swab and the
limited volume of sample recovered, which can restrict the
number of assays performed as shown by our inability to test for
b-defensins in this study. While logistically more challenging,
CVL generates significantly more sample and is commonly
performed in clinical trials. Using Normosol-R as a CVL diluent
allowed for the measurement of gluconate to quantify the amount
of mucosal secretions recovered, which was a median of 235 ml
(140–305 ml range) representing an approximate 42-fold dilution
in a 10 ml lavage. This finding is consistent with results obtained
in other studies using lithium chloride in CVL (300–500 ml)
[26,35] and fluid recovered from the InsteadH cup (0.3–0.4 g)
[36,37]. Importantly, the magnitude of the difference among the
volume of genital tract secretions recovered between women
(slightly .2-fold) was less than the variability in mediators
measured by the swabs, suggesting that cervicovaginal fluid
volume is not a major source of inter-subject variability in
concentrations of mediators or endogenous activity. This is
supported by the relatively narrow range of protein concentra-
tions measured in the CVL.
Beyond assessing cervicovaginal fluid volume, lavage diluents
containing an internal standard provide absolute concentrations
of analytes, not just relative concentration adjustments provided
by protein-based correction. The protein correction does not
correlate with the gluconate-based correction, suggesting that
these are measuring different processes. The cost of an internal
standard and its assay must be weighed against the need for
improved accuracy and precision in quantitative assessment of
cervicovaginal fluid. Due to the consistency of cervicovaginal
fluid volume among women, other investigators simply apply a
fixed dilutional correction – 42-fold with a 10 mL lavage in our
study – to correct for dilution [26,38,39].
BV is a condition common among women of reproductive age
and is accompanied by a loss of lactobacilli and an increase in
anaerobic bacteria. Women with BV have an increased risk of
HIV acquisition [27]. The reasons for the increased acquisition
are unclear, but BV has been shown to modulate the innate
immunity of the FGT [40,41,42,43]. Overall, the ability to
recover soluble mucosal immune mediators by swabs was not
affected by BV status. Women with BV had similar levels of
most mediators with the exception of significantly lower levels of
SLPI, which is consistent with others showing BV reduces SLPI
levels in the FGT [40,42]. The reduced SLPI levels were seen in
all collection methods with the exception of CVL collected in
Normosol-R. Women with BV had generally lower levels of
anti-E. coli activity as shown by the weak inverse correlation
between the two.
While the primary objective of this study was to compare
collection methods, the results provide additional data on the
range of mediators in the FGT by these diverse methods and the
relationship between them (Tables 1 and 2). Concentrations of
Lf and HNP1–3 are both produced by neutrophils and
correlated with IL-8, which would likely recruit immune cells
to the genital tract. No significant correlations between anti-
HIV-1 activity and any of the mediators were detected. This is
consistent with other studies [18,44]. Wira and colleagues found
comparable anti-HIV-1 activity in CVL from women with and
without HIV-1 infection. However, while the anti-HIV-1
activity correlated with the concentrations of HbD2, MIP3a,
and anti-HIV gp160 IgG antibodies in HIV-1-infected women,
no correlations were found in healthy women [18]. Additionally,
we found no correlation between anti-E. coli and anti-HIV-1
activity, which is consistent with prior work [45] and suggests
that immune mediators differentially contribute to host defense
against specific pathogens.
The HIV-1 prevention field has identified several gaps in the
ability to define correlates of safety and efficacy in clinical trials
[24,46]. Key to this is the best approach for mucosal sample
collection for biomarkers that can be correlated to safety and
efficacy outcomes. Findings from this study suggest that
endocervical swabs and/or CVL collected in saline may be
the optimal approaches. Endocervical sampling recovers the
highest levels of most mediators, whereas CVL in saline recovers
greater antimicrobial activity. There are limitations to both
collection methods. While swabs sample discrete sites in the
FGT, the volume of recovered sample and protein is low.
Diluting swabs in a lower volume and optimizing methods to
elute the secretions from the swabs may help mitigate this
limitation. CVL offers a large sample volume to test numerous
assays, but the lavage can dilute the mucosal fluid up to 50-fold
and low levels of important mediators may be missed. Using
both collection methods, if feasible, might provide the best
strategy, particularly since the predictive biomarkers have not
yet been identified. These results have broad implications for
microbicide and mucosal vaccine studies as well as clinical
studies designed to identify soluble mucosal mediators associat-
ed with HIV-1 risk.
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